Population-based Treatment Patterns and Outcomes for Stage III Non–Small Cell Lung Cancer Patients
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference15 articles.
1. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE);Eberhardt;J Clin Oncol,2015
2. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N Engl J Med,2017
3. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018
4. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011
5. Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis;Askoxylakis;BMC Cancer,2014
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study);Lung Cancer;2024-08
2. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study;Journal of Cancer Research and Clinical Oncology;2023-03-20
3. Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer;Journal of Thoracic Disease;2023-02
4. Pooled analysis on image‐guided moderately hypofractionated thoracic irradiation in inoperable node‐positive/recurrent patients with non–small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve;Cancer;2022-04-13
5. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non–Small Cell Lung Cancer (NSCLC);American Journal of Clinical Oncology;2022-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3